Abbvie Inc., of North Chicago, reported results at the Association for Research in Vision and Ophthalmology meeting in Denver from VISUAL I, a phase III study investigating the efficacy and safety of Humira (adalimumab) in adult patients with active non-infectious intermediate, posterior, or panuveitis who still experienced intraocular inflammation while on systemic corticosteroid therapy.